Zacks Analyst Interview Highlights: Cepheid, BioSphere Medical and Immucor

CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Tom Park, who discusses Cepheid (Nasdaq: CPHD), BioSphere Medical (Nasdaq: BSMD) and Immucor (Nasdaq: BLUD).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2678.

What was the last research report you issued, and what was your rating on the company?

Cepheid (Nasdaq: CPHD) is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical molecular diagnostic, industrial, and biothreat markets. We currently rate shares of Cepheid a Hold.

Which other companies have you reported on recently?

BioSphere Medical (Nasdaq: BSMD) develops, manufactures and markets products for medical procedures using embolotherapy techniques. Embolotherapy is the therapeutic introduction of various biocompatible substances into a patient’s circulatory system to occlude a blood vessel, either to arrest or prevent hemorrhaging or to devitalize the structure or organ by occluding its blood supply.

Any Buys or Sells in your coverage recently?

Yes, we currently have a Buy rating on Immucor (Nasdaq: BLUD), with a $35 target price. Immucor develops, manufactures, and sells a complete line of automated systems and reagents used in a number of tests to detect certain properties of the cell and serum components of human blood prior to blood transfusion. The additional worldwide placements of Galileo continue to help drive Immucor’s growth, and instrument placements are expected to be further driven by the successful launch of Echo.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks Profit from the Pros e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.